Empirical therapy advisor

Before culture results are back: how likely is each antibiotic to cover the pathogen of a patient like this one, in this ward, given the last 12 months of results and today's alerts.

Patient

More options · any onset · target 80 % · 2026-01-04
Based on 496 first isolates · MED-A · Cystitis (lower UTI) · 2025-01-05 → 2026-01-04
Internal medicine A
Per-organism detail: MED-A urine resistance view →
Narrowest option reaching 80 % coverage, no active warning
nitrofurantoin 82 % (78 %–85 %)
No tissue or blood levels: cystitis only.
Not covered: Proteus mirabilis (7 %), Pseudomonas aeruginosa (5 %), Klebsiella pneumoniae (5 %)
AntibioticCoverage, 12 months (95 % CI)12 mo4 wk
meropenem MEM
trend · Escherichia coli reserve
86 %
88 %
n = 42
nitrofurantoin NIT
trend · Escherichia coli lower UTI only
82 %
90 %
n = 42
piperacillin-tazobactam TZP
trend · Escherichia coli broad spectrum
82 %
86 %
n = 42
ciprofloxacin CIP
trend · Escherichia coli
79 %
81 %
n = 42
ceftriaxone CRO
trend · Escherichia coli
78 %
79 %
n = 42
mecillinam MEC
trend · Escherichia coli lower UTI only
78 %
79 %
n = 42
73 %
76 %
n = 42
trimethoprim TMP
trend · Escherichia coli lower UTI only
69 %
79 %
n = 42
48 %
50 %
n = 42
vancomycin VAN
trend · Enterococcus faecalis Gram-positive only
12 %
10 %
n = 42
5 %
2 %
n = 42
clindamycin CLI
trend · Staphylococcus aureus Gram-positive only
3 %
2 %
n = 42

Most likely organisms for this profile

Escherichia coli
56 %
Klebsiella pneumoniae
12 %
Enterococcus faecalis
9 %
Proteus mirabilis
7 %
Pseudomonas aeruginosa
5 %
Citrobacter freundii
4 %

Decision support only: coverage is the share of first isolates from similar patients that were susceptible (an organism not tested for a drug counts as not covered). It does not replace local treatment guidelines, allergy and severity assessment, or clinical judgement. The black tick on each bar is the coverage target; the bracket is the 95 % confidence interval.

AEI · Tyks Laboratoriot × Mylab · JunctionX Turku. Synteettinen aineisto; EARS-Net-luvut: ECDC.